Physician profile
Avery Lee Smith
NPI 1578983771
$4,391.22
in general payments reported to CMS, 2019-2025
31 companies · $1,464 in 2025
The $1,464 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $84.33 · 2021: $434 · 2022: $438 · 2023: $568 · 2024: $857 · 2025: $1,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,835 · Education: $53.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,835.05 |
| Education | $53.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,262.48 | 2019-2025 | Rinvoq, Mavyret, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $563.39 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $327.12 | 2020-2025 | |
| Celltrion USA INC. | $306.01 | 2024-2025 | Vegzelma, Zymfentra |
| Regeneron Healthcare Solutions, INC. | $294.32 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $178.55 | 2024-2025 | Tremfya, Simponi, Stelara |
| Boston Scientific Corporation | $162.33 | 2019-2025 | Exalt Model D, Resolution 360 Clip |
| Aimmune Therapeutics, INC. | $157.47 | 2024-2025 | Zenpep, Vowst |
| Qol Medical, LLC | $113.72 | 2021-2025 | Sucraid |
| Alexion Pharmaceuticals, INC. | $110.37 | 2019 | |
| Merck Sharp & Dohme LLC | $107.97 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $103.07 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.95 | 2024-2025 | Xifaxan |
| Redhill Biopharma INC. | $78.62 | 2023-2024 | Talicia |
| Intercept Pharmaceuticals, INC. | $78.47 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $65.00 | 2019 | |
| Ardelyx, INC. | $47.53 | 2025 | Ibsrela |
| Gilead Sciences, INC. | $40.79 | 2022-2025 | |
| Braintree Laboratories, INC. | $38.48 | 2021 | |
| Madrigal Pharmaceuticals | $36.33 | 2025 | Rezdiffra |
| Celgene Corporation | $33.13 | 2023 | Zeposia |
| Mallinckrodt Hospital Products INC. | $23.25 | 2025 | Terlivaz |
| Calliditas Therapeutics US INC. | $22.40 | 2024 | |
| Echosens North America, INC. | $22.34 | 2024 | Fibroscan |
| Vivus LLC | $21.25 | 2024 | Pancreaze |
| Lilly USA, LLC | $20.86 | 2025 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.85 | 2024 | Cyltezo |
| Aries Pharmaceuticals, INC. | $18.24 | 2019 | |
| Ferring Pharmaceuticals INC. | $18.10 | 2021 | |
| Novo Nordisk INC | $16.84 | 2025 | |
| Endo USA, INC. | $13.99 | 2025 | Xiaflex, Aveed |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avery Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.